Infectious Diseases
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Pfizer Divests Select China Prevenar 13 Rights, Staff As Domestic Firms Gain Traction
Following in the steps of Merck & Co. and GSK, Pfizer is turning to a Chinese partner to more broadly market one of its top vaccines in the country - but the US firm is going one step further.

Global Health Leaders Highlight Pandemic Preparedness
At the recent World Bio Summit in Seoul, global health leaders discussed international cooperation strategies and policies to prepare for the next pandemic, with a focus on rapid vaccine development.

Lilly’s Zepbound: The Biggest-Selling Drug In The World, Ever?
Humira currently holds the record as the bestselling drug ever. But Keytruda is coming for its crown – and beyond that, Zepbound.

All About Scale: GSK Eyes China Partnerships To Ramp Up Vaccine Access
GSK is betting on a new partnership to more quickly ramp up patient access to its vaccines in the potentially vast market of China, amid rising demand and competition.

Innoviva Aims For A First-In-Class Antibiotic
Zoliflodacin could become the first new antibiotic for treating gonorrhea in decades, but can it change guidelines?

A Stellar Launch For RSV Vaccine Arexvy Lifts GSK
GSK has enjoyed a better-than-expected launch for its RSV vaccine, but emphasized that it was still early days, and the firm is not altering its £3bn peak annual sales forecast for the product.

GSK Takes Over J&J/Arrowhead Hep B Candidate For Combo Development
Deal Snapshot: Seeking to develop a combination regimen for chronic hepatitis B, GSK acquires rights to J&J/Arrowhead’s siRNA candidate JNJ-3839 to pair with its antisense candidate bepiroversen.

In Competitive RSV Market, GSK Aims To Be First For Adults 50-59
Results from a Phase III trial testing the RSV vaccine Arexvy in adults 50-59 met the two primary endpoints, potentially opening the door to a wider adult market.

It’s Official: The Merck-Daiichi Deal Has The Biggest Upfront Ever
But the partners will have to avoid the pitfalls that have bedevilled several other expensive licensing deals.

Gilead Adds To Virology Focus Through 12-Year Collaboration With Assembly
Gilead gets option rights to Assembly’s entire virology pipeline, including future assets, for herpesvirus and hepatitis B and D. The deal provides financial stability and opt-in potential for Assembly.

Moderna Marches Into Phase III With COVID/Flu Vaccine Combo
The US biotech major says that preliminary data show that its mRNA-1083 combination vaccine yielded antibody levels in the blood similar to or greater than two Sanofi flu vaccines and its own COVID-19 shot Spikevax.

ViiV In It For The Long Haul In HIV Market Battle With Gilead
The GSK-led joint venture has taken the lead in long-acting HIV treatment and prevention but has put back timelines on a key self-administered candidate.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.